Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Fears of global aluminum shortages intensify - 2What is IDF's view on pontential long-term occupation of southern Lebanon?
- 3Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- 4The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
- 5Germany's first Omani LNG shipments arrive despite Middle East disruptions
- Is Iran using cryptocurrencies to circumvent sanctions?
- Share your pick for the riding area that characterizes your surf undertakings!
- The Best Portable Applications for Emotional wellness and Prosperity
- Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- 'Heated Rivalry' is just the tip of the iceberg. How hockey became the sexiest sport
- What's going around right now? COVID, flu, stomach bug on the rise
- After fleeing past Hezbollah fighting, some Israelis on northern border vow to stay
- 6 Trail blazing Bicycles for Rough terrain Undertakings
- German diesel hits new records over Easter weekend
